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Background: The glucagon-like peptide-1 receptor (GLP1R) agonist liraglutide improves glycemic control and
reduces body weight of adult type 2 diabetic patients. However, efficacy and safety of liraglutide in adolescents
has not been systematically investigated. Furthermore, possible pro-proliferative effects of GLP1R agonists on the
endocrine and exocrine pancreas need to be further evaluated. We studied effects of liraglutide in adolescent pigs
expressing a dominant-negative glucose-dependent insulinotropic polypeptide receptor (GIPRdn) in the beta-cells,
leading to a pre-diabetic condition including disturbed glucose tolerance, reduced insulin secretion and progressive
reduction of functional beta-cell mass.
Methods: Two-month-old GIPRdn transgenic pigs were treated daily with liraglutide (0.6-1.2 mg per day) or placebo
for 90 days. Glucose homeostasis was evaluated prior to and at the end of the treatment period by performing
mixed meal and intravenous glucose tolerance tests (MMGTT and IVGTT). Finally animals were subjected to
necropsy and quantitative-stereological analyses were performed for evaluation of alpha- and beta-cell mass,
beta-cell proliferation as well as acinus-cell proliferation.
Results: MMGTT at the end of the study revealed 23% smaller area under the curve (AUC) for glucose, a 36% smaller
AUC insulin, and improved insulin sensitivity, while IVGTT showed a 15% smaller AUC glucose but unchanged AUC
insulin in liraglutide- vs. placebo-treated animals. Liraglutide led to marked reductions in body weight gain (-31%) and
food intake (-30%) compared to placebo treatment, associated with reduced phosphorylation of insulin receptor
beta (INSRB)/insulin-like growth factor-1 receptor beta (IGF1RB) and protein kinase B (AKT) in skeletal muscle.
Absolute alpha- and beta-cell mass was reduced in liraglutide-treated animals, but alpha- and beta-cell mass-to-body
weight ratios were unchanged. Liraglutide neither stimulated beta-cell proliferation in the endocrine pancreas
nor acinus-cell proliferation in the exocrine pancreas, excluding both beneficial and detrimental effects on the
pig pancreas.
Conclusions: Although plasma liraglutide levels of adolescent transgenic pigs treated in our study were higher
compared to human trials, pro-proliferative effects on the endocrine or exocrine pancreas or other liraglutide-related
side-effects were not observed.
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GLP1R agonists represent a promising group of incretin-
based therapeutics for type 2 diabetes [1]. Liraglutide is
approved for the use in adult type 2 diabetic patients [2]
and was shown to reduce body weight and improve gly-
cemic control to a greater extent than exenatide [3-5].
Since the prevalence of type 2 diabetes is steadily increas-
ing among adolescents while only few approved therapeu-
tics exist, liraglutide can possibly address the unmet need
for treatment of this group of patients [6]. However, ef-
fects of liraglutide on adolescents have not been systemat-
ically studied. The use of an adolescent animal model is
important to gain insight into efficacy and safety of liraglu-
tide in adolescent patients but also to evaluate possible
pro-proliferative effects of incretin-based therapies in the
endocrine and exocrine pancreas at a young age with pre-
sumably high cell proliferation capacity [7,8]. So far, stud-
ies in non-rodent species are rare but consistently showed
no positive effect of liraglutide treatment on endocrine cell
mass and proliferation rate [9-11]. Studies in numerous
different rodent models that evaluated the effect of the
GLP1R agonist liraglutide on beta-cell mass, proliferation
and apoptosis showed variable results. While some of
them revealed a substantial increase in beta-cell mass up
to almost 40% and positive effects on beta-cell prolifera-
tion rate, others detected unaltered or even reduced beta-
cell mass and/or proliferation rate [12-19]. But it has to be
taken into account that the rodent pancreas has higher
capacity for beta-cell proliferation compared to the human
pancreas [20,21]. Therefore, findings in rodents do not ne-
cessarily reflect effects of liraglutide on human beta-cells.
Also, rodent studies suggested a pro-proliferative influence
of GLP1R agonists on the exocrine pancreas [22-24], and
a recent study even reported marked expansion of exo-
crine tissue and a potential risk for neuroendocrine tu-
mors in human pancreata after incretin therapy [25]. As
results from rodent studies are inconsistent, studies in
non-rodent species as well as cadaveric organs of patients
with incretin therapy are rare, and the in vivo monitoring
of cell proliferation in human pancreata is still challenging,
studies with large animal models may improve the under-
standing of GLP1 analogue action on cell proliferation in
the pancreas and associated side-effects. The pig is physio-
logically similar to human and thus has the potential to
bridge the gap between rodent models and human pa-
tients [26,27]. Transgenic pigs expressing a GIPRdn in
their beta-cells mimic important aspects of human pre-
diabetes: impaired function of the incretin hormone GIP,
disturbed glucose tolerance, reduced insulin secretion, and
progressive reduction of beta-cell mass [7,28]. Since the
function of the GLP1R is not disturbed in this pig model
[7], we performed a treatment trial with the GLP1R agon-
ist liraglutide in order to address the following questions:
1.) How does liraglutide physiologically affect adolescentorganisms? 2.) Can liraglutide maintain or expand physio-
logical beta-cell mass? 3.) Does liraglutide induce cell pro-
liferation in the endocrine or exocrine pancreas?
Methods
Animals and study design
Eighteen hemizygous GIPRdn transgenic pigs [7] were
randomly assigned to liraglutide treatment using pre-
filled pens (Victoza®, 6 mg/ml, Novo Nordisk A/S) or
placebo treatment (0.9% NaCl, B. Braun), injected sub-
cutaneously once daily for 90 days. Liraglutide doses
(0.6-1.2 mg per day, Figure 1A) were based on human
dosages adjusted for pig body weight. Pigs were housed
in planar single pens with straw litter and had ad libitum
access to water and a standard pig diet (see Additional
file 1: Table S1 for diet composition). All animal experi-
ments were performed in accordance with the German
Animal Welfare Act and approved by the responsible
animal welfare authority. Pigs were treated with liraglutide
(n = 9; 5 females, 4 males) or placebo (n = 9; 5 females, 4
males) from 2 to 5 months of age. At the age of 2 months
untreated GIPRdn transgenic pigs show disturbed oral glu-
cose tolerance and delayed insulin secretion, but unaltered
total beta-cell volume [7]. The physiological characteristics
of the pigs prior to liraglutide/placebo treatment are sum-
marized in Table 1.
Measurements of body weight and food intake
Body weight was determined once weekly to the nearest
0.5 kg and food intake was recorded per 3 days. Feeding
efficiency corresponds to total body weight gain divided
by entire food intake during the treatment period. Ani-
mals were monitored daily for side effects.
Clinical chemistry
Blood samples were taken every month after an 18-hour
fasting period. Serum was separated by centrifugation
and analyzed for standard clinical-chemical parameters
using an Autoanalyzer Hitachi 911® and adapted re-
agents from Roche Diagnostics GmbH.
Glucose tolerance test
A mixed meal glucose tolerance test (MMGTT) as well as
an intravenous glucose tolerance test (IVGTT) was per-
formed prior to and at the end of the 90-day treatment
period after an 18-hour fasting period. Central venous
catheters (Cavafix® Certo®, B. Braun) were surgically
inserted into the external jugular vein and the tests were
performed as described previously [7]. For the MMGTT
2 g glucose/kg body weight mixed with 50-200 g pig fod-
der (Deuka porfina U, Deuka) depending on the body
weight of the pigs were administered. For the IVGTT a
bolus injection of concentrated 50% glucose solution
(0.5 g per kg body weight) was administered through the
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Figure 1 Study design and plasma liraglutide levels. (A) Study outline/liraglutide dosage regimen, mo =months of age, GTT = glucose tolerance
testing including mixed meal glucose tolerance test (MMGTT) and intravenous glucose tolerance test (IVGTT). (B) Plasma liraglutide levels at the end of
the treatment period in non-fasted GIPRdn transgenic pigs after 1.2 mg liraglutide injection; 0 hours = point of liraglutide administration.
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tered 3 hours before the test. Plasma glucose/insulin levels
were measured as described previously [7] and plasma
glucagon levels were determined by radioimmunoassay
(Millipore). The net glucose elimination rate after glucose
injection was calculated as the slope for the interval 1-30Table 1 Physiological characteristics of GIPRdn transgenic
pigs one week prior to the start of liraglutide/placebo
treatment
Parameter Control group Treatment group P
(Placebo) (Liraglutide)
n = 9 n = 9
4 m, 5 f 4 m, 5 f
Age [days] 60 ± 0.14 60 ± 0.14 1.00
Body weight [kg] 15 ± 1.00 16 ± 0.73 0.41
MMGTT
AUC glucose 17839 ± 682 18375 ± 881 0.80
AUC insulin 2956 ± 187 3296 ± 261 0.30
IVGTT
AUC glucose 13015 ± 592 12821 ± 458 0.86
AUC insulin 719 ± 69 862 ± 75 0.08
m=male, f = female, MMGTT = mixed meal glucose tolerance test,
IVGTT = intravenous glucose tolerance test, AUC = area under the curve.
Data are means ± SEM.minutes after glucose injection of the logarithmic trans-
formation of the individual plasma glucose values [29].
Plasma liraglutide levels
At the end of the treatment period, plasma liraglutide
levels were determined in non-fasted animals after injec-
tion of 1.2 mg liraglutide. Blood samples were collected
at 0, 4, 8, 12 and 16 hours relative to liraglutide adminis-
tration in EDTA monovettes pre-treated with diprotin A
(Sigma-Aldrich) and aprotinin (Roth). Liraglutide levels
were measured by Novo Nordisk A/S, using an in-house
luminescence oxygen channeling immunoassay validated
for pig plasma.
Insulin sensitivity
To evaluate insulin sensitivity the HOMA-IR and the in-
sulin sensitivity index according to Matsuda [ISI(Matsuda)]
were calculated [30].
Necropsy and pancreas sampling
Following the treatment period pigs were euthanized and
selected organs were weighed. A subgroup of liraglutide-
(n = 5) and placebo-treated animals (n = 4) was fasted for
12 hours before necropsy to assess effects on gastric
emptying. The pancreas was explanted in toto, connective
tissue was separated and the organ was weighed. Twenty
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random sampling and routinely processed for paraffin
histology [7]. Skeletal muscle samples were taken from the
biceps brachii muscle, shock frozen, and stored at -80°C.
Immunohistochemistry and quantitative-stereological
analyses
For histological evaluation and quantitative-stereological
analyses sections of 20 different pancreas positions were
investigated. Sections were stained with hematoxylin
and eosin (H&E) for detailed histological assessment by
two independent pathologists. Insulin-containing cells
were stained using guinea pig anti-porcine insulin anti-
bodies (1:1000, Dako Cytomation) and goat anti-guinea
pig IgG (1:100, Southern Biotech) with Vector® Red
(Vector Laboratories Inc.) as chromogen. Glucagon-
containing cells were stained with rabbit anti-glucagon
antibodies (1:300, Dako) and goat anti-rabbit IgG (1:100,
Dako) visualized with DAB (Biotrend). Mayer’s hemalum
(Applichem GmbH) served as counterstain. Quantifica-
tion of alpha-/beta-cell volume was carried out using the
Visiomorph™ image analysis system (Visiopharm A/S).
Volume densities [Vv(alpha-cell/Pan), Vv(beta-cell/Pan)] as well as
total alpha-/beta-cell volume [V(alpha-cell, Pan), V(beta-cell, Pan)]
were determined as described previously [7] and the corre-
sponding alpha-/beta-cell volume-to-body weight ratios
were calculated. Proliferation of beta-cells/acinus-cells was
determined in sections co-stained with mouse anti-human
Ki67 antibodies (1:8, Dako) and goat anti-mouse IgG (1:20,
Dako) with BCIP/NBT Substrate Kit (Vector Laboratories
Inc.) as chromogen as well as guinea pig anti-porcine insu-
lin antibodies (1:1000, Dako) and rabbit anti-guinea pig
IgG (1:100, Southern Biotech) with DAB as chromogen
and Mayer’s hemalum as counterstain. Sections were
systematically sampled using the stereology software
newCast (Visiopharm) and cell proliferation was quanti-
fied as the number of Ki67+ labeled beta-cell/acinus-
cell nuclei profiles divided by the total number of beta-cell/
acinus-cell nuclei profiles counted and expressed as the
number of Ki67+ labeled cell nuclei profiles per 105 cell
nuclei profiles.
Western blot analyses
For protein extraction, muscle tissue was homogenized in
Laemmli-extraction buffer, and the protein content was
determined by the bicinchoninic acid protein assay. 40 μg
of total protein was separated by SDS-PAGE and trans-
ferred to PDVF membranes (Millipore) by electroblotting.
Membranes were washed in Tris-buffered saline solution
with 0.1% Tween-20 and blocked in 5% w/v fat-free
milk powder (Roth) for 1 h. Then membranes were
washed again and incubated in 5% w/v BSA (Roth) solu-
tion with the appropriate primary antibody (Additional
file 2: Table S2) overnight at 4°C. After washing, membraneswere incubated in 5% w/v fat-free milk powder with a
secondary antibody (donkey anti-rabbit; 1:2000; GE-
Healthcare) for 1 h. Bound antibodies were detected using
an enhanced chemiluminescence detection reagent (ECL
Advance Western Blotting Detection Kit, GE Healthcare)
and appropriate films (GE Healthcare). After detection,
membranes were stripped and incubated with a second
antibody. Band intensities were quantified using the Ima-
geQuant software package (GE Healthcare).
Statistics
All data are presented as means ± SEM. For statistical
analysis, longitudinal data were square-root trans-
formed to approximate normal distribution. Since sig-
nificant deviations from normal distribution were only
rarely detected (Shapiro-Wilk test in the Univariate
Procedure; SAS 8.2), transformed data for body weight,
food intake, glucose, insulin and glucagon levels were
evaluated by ANOVA (Linear Mixed Models; SAS 8.2)
taking the fixed effects of Group (liraglutide-/placebo-
treated), Time (relative to glucose administration/treat-
ment duration), and the interaction Group*Time into
account. Transformed data of clinical-chemical analyses
were evaluated by ANOVA (General Linear Models;
SAS 8.2) taking the fixed effects of Group, Age, and the
interaction Group*Age into account. AUC insulin/glu-
cose was calculated using GraphPad Prism® software
(version 5.02). AUCs and all remaining parameters were
tested for significance by Mann-Whitney-U-test using
GraphPad Prism® software. Results of Western blot ana-
lyses were related to the mean value of the placebo
group (set to 1) and presented as box-plots with me-
dian. P values less than 0.05 were considered significant.
Net glucose elimination rates [29] were calculated and




Individual plasma liraglutide levels ranged between 17.8
and 56.6 nmol/l (Figure 1B). The highest mean plasma
liraglutide levels were determined in the plasma sample
8 hours after application.
Reduced body weight gain
Liraglutide-treated GIPRdn transgenic pigs gained dis-
tinctly less body weight compared to their placebo-
treated counterparts, resulting in a 31% reduced body
weight (63.7 ± 2.4 kg vs. 91.6 ± 3.7 kg; p < 0.001) at the
end of the 90-day treatment period (Figure 2A). In
addition to the reduced body weight, liraglutide-treated
pigs appeared slightly smaller in size and shape than the
corresponding placebo-treated pigs (for representative
examples, see Figure 2B).
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Figure 2 Body weight gain and food intake in liraglutide- and placebo-treated GIPRdn transgenic pigs. (A) Body weight gain of
GIPRdn transgenic pigs during pre-treatment and treatment period, black arrows indicate beginning/end of liraglutide/placebo administration.
(B) Representative physical appearance of two female littermates (L = liraglutide-treated pig, P = placebo-treated pig) during the last third of
the treatment period. (C) Food intake and (D) feeding efficiency of liraglutide- vs. placebo-treated GIPRdn transgenic pigs during the treatment
period, n = number of animals investigated. Data are means ± SEM. For statistical analysis (ANOVA; Linear Mixed Models; SAS 8.2), data were
square-root transformed. *: p < 0.05, **: p < 0.01, ***: p < 0.001.
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Generally, pigs showed a steadily increasing food intake
(Figure 2C). Nevertheless, liraglutide caused an immediate
and sustained significant decrease in food intake compared
to placebo, with mean differences of 30% (Figure 2C).
Additionally, feeding efficiency was significantly re-
duced in liraglutide- vs. placebo-treated GIPRdn trans-
genic pigs (Figure 2D).Health status and clinical-chemical parameters
During the treatment period, the general condition of all
animals was undisturbed and adverse gastrointestinal
effects like vomiting, obstipation or diarrhea were not
observed. Clinical-chemical analyses revealed no differ-
ences between liraglutide- and placebo-treated GIPRdn
transgenic pigs in most parameters measured. However,
liraglutide-treated pigs showed significantly lower serum
levels of total protein (-8.6 ± 0.2%, p < 0.001), albumin
(-12.7 ± 1.7%, p < 0.05) and phosphate (-11.8 ± 4.7%,
p < 0.01) compared to their placebo-treated counter-
parts. Additionally, alkaline phosphatase (AP) activity
was significantly increased in liraglutide-treated pigs
(+10.4 ± 0.5%, p < 0.01) (see Additional file 3: Table S3).Improved oral glucose tolerance, decreased insulin
secretion, and improved insulin sensitivity
GIPRdn transgenic pigs allocated to the liraglutide and
placebo treatment groups did not show significant differ-
ences in glucose tolerance and insulin secretion during
MMGTT and IVGTT performed prior to treatment
(Table 1). However, during the second MMGTT at the
end of the 90-day treatment period, plasma glucose in-
creased much less in liraglutide- than in placebo-treated
pigs, resulting in a 23% smaller AUC glucose (p < 0.001,
Figure 3A). Accordingly, AUC insulin of liraglutide-
treated pigs was 36% reduced (p < 0.05; Figure 3B) as
compared to their placebo-treated counterparts. Gluca-
gon levels during the MMGTT were not significantly
different between liraglutide- and placebo-treated ani-
mals (Figure 3C). Moreover, liraglutide markedly improved
insulin sensitivity, as shown by significantly reduced
HOMA-IR and increased ISI(Matsuda) after the treatment
period (Figure 3D). The IVGTT at the end of the treatment
period revealed a 15% decreased AUC glucose in
liraglutide- vs. placebo-treated animals (p < 0.01; Figure 4A).
The slopes of the net glucose elimination rate for the pla-
cebo (P: -0.0274 ± 0.0014) and liraglutide (L: -0.0355 ±
0.0011) groups were significantly different (p <0.001;































































































































Figure 3 Glucose control and insulin sensitivity during MMGTT in liraglutide- and placebo-treated GIPRdn transgenic pigs. (A) Plasma
glucose levels and AUC glucose as well as (B) plasma insulin levels and AUC insulin and (C) plasma glucagon levels and AUC glucagon during MMGTT
in 18-hour fasted GIPRdn transgenic pigs after the 90-day treatment period, 0 min. = point of glucose administration. (D) Insulin sensitivity indices prior
to (2-month-old pigs) and after the treatment period (5-month-old pigs), mo =months of age, n = number of animals investigated. Data are means ± SEM.
For statistical analysis (ANOVA; Linear Mixed Models; SAS 8.2), data were square-root transformed. *: p < 0.05, **: p < 0.01, ***: p < 0.001.
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ment groups (p = 0.73), although insulin levels were a ten-
dency higher at the first time points after glucose
administration and significantly lower at time points 40 and
50 minutes after glucose administration in liraglutide- vs.
placebo-treated animals (Figure 4B).Effects on gastric emptying and organ weights
Liraglutide-treated animals showed a general tendency
of lower absolute organ weights, while relative organ
weights tended to be increased. Absolute pancreas weight
of liraglutide- and placebo-treated pigs was 104.9 ± 3.7 g
and 118.1 ± 8.4 g (p = 0.260). Relative pancreas weight






















































































Figure 4 Glucose control during IVGTT in liraglutide- and placebo-treated GIPRdn transgenic pigs. (A) Plasma glucose levels and AUC
glucose as well as (B) plasma insulin levels and AUC insulin during IVGTT in 18-hour fasted GIPRdn transgenic pigs after the 90-day treatment
period, 0 min. = point of glucose administration, n = number of animals investigated. Data are means ± SEM. For statistical analysis (ANOVA;
Linear Mixed Models; SAS 8.2), data were square-root transformed. *: p < 0.05, **: p < 0.01, ***: p < 0.001. The insert in panel (A) shows the net
glucose elimination rate after glucose injection as calculated as the slope for the interval 1–30 min after glucose injection of the logarithmic
transformation of the individual plasma glucose values. The slopes of the net glucose elimination rate for the placebo (P: -0.0274 ± 0.0014) and
liraglutide (L: -0.0355 ± 0.0011) groups were significantly different (p <0.001).
Streckel et al. Journal of Translational Medicine  (2015) 13:73 Page 7 of 13was significantly increased in liraglutide-treated vs.
placebo-treated animals (0.165 ± 0.005 and 0.127 ±
0.005, p < 0.001). At necropsy, the stomach of 12-hour-
fasted liraglutide-treated animals still contained large
amounts of food, while the stomach of placebo-treated
animals was empty or filled with liquid.
Reduced total alpha-cell volume, total beta-cell volume
and beta-cell proliferation, but unaltered acinus-cell
proliferation
Quantitative-stereological analyses of pancreatic sec-
tions immunohistochemically stained for insulin
(Figure 5A) revealed a reduced total beta-cell volume
in liraglutide- vs. placebo-treated pigs with borderline
significance (745.70 mm3 vs. 957.82 mm3, p = 0.062,
Figure 5B). However, the total beta-cell volume-to-
body weight ratio was not different between
liraglutide- and placebo-treated animals (p = 0.34, Fig-
ure 5C). Total alpha-cell volume was reduced by 30%
in liraglutide- compared to placebo-treated pigs (p <
0.05, Figure 5E). However, no differences were visible
when alpha-cell mass was related to body weight (p =
0.93, Figure 5F). Proliferation rate of beta-cells was sig-
nificantly reduced by 17% in liraglutide- vs. placebo-treated pigs (p < 0.01, Figure 5H). Acinus-cell prolifera-
tion did not differ between liraglutide- and placebo-
treated animals (p = 0.86, Figure 5I). Evaluation of H&E
stained pancreatic sections did not reveal histological
abnormalities in the endocrine or exocrine pancreas of
liraglutide-treated animals.Reduced activation of the growth related insulin signaling
pathway in skeletal muscle
Western blot analyses investigating the growth regulat-
ing mammalian target of rapamycin (mTOR) complex
including up- and downstream pathways revealed de-
creased phosphorylation of the INSRB/IGF1RB and
AKT and increased phosphorylation of eukaryotic initi-
ation factor 4E binding protein (4EBP1) in liraglutide-
vs. placebo-treated pigs (p < 0.05, Figure 6). The phos-
phorylation status of mTOR, AMP-activated protein
kinase (AMPK), S6 kinase 1 (S6K1) and glycogen
synthase kinase 3 beta (GSK3β) was not affected by lira-
glutide treatment. The amount of the eukaryotic trans-
lation initiation factor 4E (elF4E) was significantly















































































































































Figure 5 Quantitative-stereological analyses of pancreata from liraglutide- and placebo-treated GIPRdn transgenic pigs. Representative
histological pancreas sections of (A) immunohistochemical staining for insulin and (D) glucagon as well as (G) double immunohistochemical
staining for Ki67 (blue) and insulin (brown) of liraglutide- (L) and placebo-treated (P) GIPRdn transgenic pigs, red arrow: proliferating beta-cell,
white arrow: proliferating acinus-cell, scale bar = 50 μm. (B) Total beta-cell volume [V(beta-cell, Pan)] and (C) total beta-cell volume related to
body weight [V(beta-cell, Pan)/BW] as well as (E) total alpha-cell volume [V(alpha-cell, Pan)] and (F) total alpha-cell volume related to body weight
[V(alpha-cell, Pan)/BW]. (H) Beta-cell proliferation rate and (I) acinus-cell proliferation rate. Data are means ± SEM, *: p < 0.05, **: p < 0.01.
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The present study evaluated the effect of a 90-day lira-
glutide treatment on growth, food intake, glycemic con-
trol, as well as endocrine and exocrine pancreas in
adolescent transgenic pigs showing key characteristics of
a pre-diabetic state. Liraglutide was the GLP1R agonist
of choice as it improved glycemic control in adult type 2
diabetic patients more effectively than exenatide [4,5].
In contrast to clinical trials with adult type 2 diabetic
patients that report weight loss of few percent [3], the
body weight gain reducing effect in adolescent pigs was
markedly more pronounced. This may be due to several
factors: First, plasma liraglutide levels of pigs used in
the present study were higher than in humans treated
with the same dose (1.2 mg), most likely due to the
higher overall bioavailability of liraglutide in pigs [2].
Additionally, the GIPRdn transgenic pig model showsa compensatory enhanced effect to exendin-4 during
stimulation tests and thereby seems to be especially sen-
sitive to GLP1 [7]. Furthermore it has to be taken into
account that adolescent organisms could be more sensi-
tive to GLP1R agonist treatment compared to adult sub-
jects. Human clinical studies investigating the influence
of liraglutide in adolescents are rare and only outcomes
from small clinical trials are available to date, despite of
a steadily increasing prevalence of type 2 diabetes in
youth [6,31]. One study in adolescent type 2 diabetic
subjects treated with liraglutide did not detect alter-
ations in body weight [32] while a case report noted a
slight weight increase after 2 months of liraglutide treat-
ment [33]. Due to the relatively slow growth of human
adolescents, effects of liraglutide on growth and weight
gain are unlikely to be detected during short treatment




































Figure 6 Western blot analysis of the mTOR mediated insulin-stimulated pathway. (A) Overview of the growth-regulating mTOR signaling
pathway. (B) Western blot analyses of protein extracted from skeletal muscle showing blots of phosphorylated (upper panel) and not phosphorylated
(lower panel) up- and down-stream regulators of the mTOR pathway in liraglutide- (left side of the blot) and placebo-treated (right side of the blot)
GIPRdn transgenic pigs. For elF4E not phosphorylated molecule (upper panel) is referred to tubulin (lower panel). (C) Quantitative analysis of Western
blot signals, results are expressed as ratio of phosphorylated to not phosphorylated regulator and for eIF4E as absolute fold expression,
related to the mean value of the placebo group, respectively, and presented as box plots with median, n = number of animals investigated,
black plots = liraglutide-treated animals, white plots = placebo-treated animals, * = p < 0.05.
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thus providing a sensitive test system for detecting
growth related drug effects within a reasonable period of
time. Nevertheless translation of findings of the present
study to adolescent type 2 diabetic patients is limited by
the fact that the dose of liraglutide was higher than in
previous studies in pigs [35,36], resulting in higher
plasma liraglutide levels compared to human trials [2].Further, the pigs used in the present study were not
obese, while most adolescent type 2 diabetic patients
show concomitant obesity, which may further decrease
liraglutide levels and modulate its biological effects.
The reduced food intake observed in liraglutide-
treated pigs is probably due to the known ability of lira-
glutide to delay gastric emptying [13,35,36]. Notably,
after a 12-hour fasting period at the end of the 90-day
Streckel et al. Journal of Translational Medicine  (2015) 13:73 Page 10 of 13treatment, liraglutide-treated pigs still had large amounts
of food in their stomach, excluding adaptation of stom-
ach emptying against liraglutide treatment or even
tachyphylaxis. Our observations in the juvenile pig
model contrast studies in young rats suggesting delayed
gastric emptying as an acute effect of liraglutide treat-
ment [37]. Reduced food intake may lead to a condition
of undernutrition in the period of rapid growth as sup-
ported by reduced serum total protein and albumin
concentrations. Significantly reduced serum phosphate
concentrations in liraglutide-treated pigs may point to
an effect on bone growth and/or metabolism, which is in
line with the smaller appearance of the liraglutide-
treated animals. In addition, liraglutide significantly re-
duced feeding efficiency, indicating a lower capability to
dispose the food taken up. Studies in rodents suggested
that liraglutide treatment increases energy expenditure
[38,39], which remains to be determined in our pre-
diabetic pig model.
Reduced insulin secretion in liraglutide-treated pigs
corresponds to markedly decreased AUC glucose during
MMGTT, most likely due to impaired gastric emptying
and therefore delayed intestinal absorption of glucose
[36,40]. Although liraglutide is a potent GLP1R agonist,
it is likely that its insulinotropic effect depends on ele-
vated glucose levels, as described for GLP1 [41]. Add-
itionally, insulin sensitivity was – in accordance with
findings in rodent and pig models [13,35,38,39,42] and
with clinical studies [43] - significantly improved by lira-
glutide treatment, reducing the amount of insulin re-
quired for glucose disposal. This is also supported by the
improved intravenous glucose tolerance observed in
liraglutide-treated pigs. However, since our study did not
include a weight-matched control group, we cannot ex-
clude that the improved insulin sensitivity of the
liraglutide-treated pigs is – at least in part – due to their
reduced body weight gain.
The markedly reduced insulin secretion observed dur-
ing MMGTT, which mimics normal food intake, may
also have contributed to impaired body weight gain. This
is supported by the fact that INSC94Y transgenic pigs,
which exhibit reduced insulin secretion, also show a
markedly reduced body weight gain [44]. To address this
hypothesis, we first performed holistic transcriptome
analyses (available at Gene Expression Omnibus, record
GSE56427) of biceps brachii muscle samples using Affy-
metrix custom Gene ST arrays (SNOWBALLs520824F)
as previously described [28]. Skeletal muscle was chosen
as a primary target tissue for insulin actions [45] and a
major constituent of pig body weight. Our analysis re-
vealed some sex-dependent transcriptome differences
but no effects related to liraglutide treatment/reduced
insulin secretion were found. To determine the phos-
phorylation status of proteins of the insulin signalingpathway which are known to regulate growth and to be
modulated by insulin and nutrient uptake, we performed
Western blot analyses [46,47]. Liraglutide treatment and
concomitantly reduced insulin levels resulted in reduced
phosphorylation of INSRB/IGF1RB and AKT. Although
there was no significant change in the phosphorylation
status of mTOR, we observed increased phosphorylation
of the downstream regulator 4EBP1, which releases eIF4E,
allowing initiation of translation [46,48]. Nevertheless, the
level of free eIF4E was reduced in liraglutide-treated ani-
mals. Taken together, these findings point to reduced acti-
vation of the insulin signaling pathway in skeletal muscle
of liraglutide- compared to placebo-treated pigs [46-48].
In the present study, liraglutide treatment did not
stimulate beta-cell proliferation or increase total beta-
cell mass in comparison to placebo treatment. This con-
trasts rodent studies reporting an increase in beta-cell
mass after liraglutide treatment, going along with en-
hanced beta-cell proliferation and/or decreased beta-cell
apoptosis [12-14]. These studies showed that two weeks
of liraglutide administration (200 μg/kg twice daily) in
diabetic db/db mice causes a beta-cell volume increase
of about 35%, accompanied by an enhanced beta-cell
proliferation rate [12,14]. Two weeks of liraglutide treat-
ment (200 μg/kg twice daily) resulted in a 30% increased
beta-cell volume going along with improved beta-cell
proliferation in normoglycemic m/m mice [14], and six
weeks of liraglutide treatment (30 μg or 150 μg twice
daily) provoked increased beta-cell volume in Zucker
diabetic fatty rats [13]. However, findings in rodent stud-
ies show a broad variability, as the same animal strains
treated with lower dosages or exhibiting a different
metabolic status show unaltered or even reduced beta-
cell volume after liraglutide treatment [12,13,38,42]. This
suggests strong influence of variable parameters like
strain, age, metabolic status and glycemic control, dur-
ation of treatment and dosage that may altogether
modulate the effect of liraglutide treatment on the ro-
dent organism [12]. Additionally, it has to be taken into
account that the rodent pancreas shows higher capacity
for beta-cell proliferation compared to the human pan-
creas [20,21], and that – due to the shorter half-life of
liraglutide in rodents (4-8 h) vs. humans (13-15 h) and
pigs (14 h) [2] – liraglutide was administered twice daily
in rodents. Studies investigating the effect of GLP1R ag-
onists in non-rodent models like pigs or monkeys are
rare, however provide more consistent results. In pan-
creaticoduodenectomized Yucutan miniature pigs that
received an infusion of a marginal mass of pancreatic is-
lets into the portal circulation, a six-week administration
of liraglutide (20 μg/kg maintenance dose) could im-
prove metabolic function of the animals, but the quanti-
tative proportion of beta-cells in the transplanted islets
did not differ between liraglutide- and placebo-treated
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molgus monkeys (52-week duration using a dose up to
5 mg/kg/day) resulted in unaltered endocrine cell mass
and proliferation rate [9,10].
Liraglutide-treated pigs of the present study exhib-
ited only a moderate increase in plasma glucose after
food intake, reducing the demand for insulin secretion
and beta-cell proliferation. When related to body weight,
total beta-cell mass was not different between liraglutide-
and placebo-treated pigs which is in accordance with
previous reports describing a linear correlation between
beta-cell mass and body weight in rats and pigs [49,50].
Total alpha-cell mass was significantly reduced in
liraglutide- vs. placebo-treated GIPRdn transgenic pigs,
while alpha-cell distribution was not different between
liraglutide/placebo treatment. This is not in agreement
with the increase of alpha-cell mass and abnormal
alpha-cell distribution seen in pancreata of type 2
diabetic patients after incretin therapy [25]. The authors
suggested reduced glucagon secretion induced by GLP1R
agonist treatment as a fundamental reason [25]. How-
ever, in our study glucagon levels in liraglutide-treated
pigs did not differ from those of placebo-treated pigs.
Additionally, our finding reproduces the reduced alpha-
cell mass observed in normoglycemic mice after liraglu-
tide treatment [42].
Recent studies raised concern that incretin treatment
might be accompanied by a proliferative effect on the
exocrine pancreas, leading to histological changes, pan-
creatitis and an increased risk of pancreatic cancer in
the long run [22-25,42], although these observations
were not confirmed by other reports [9,17,51-54]. As the
relative pancreas weight of liraglutide-treated pigs was
increased compared to placebo-treated animals, we de-
termined the proliferation rate of acinus-cells in the exo-
crine pancreas, but did not detect differences following
liraglutide treatment. Therefore we exclude a prolifera-
tive effect of liraglutide on the exocrine pancreas in the
GIPRdn transgenic pig model. This is in line with studies
investigating Cynomolgus monkeys and rats under incre-
tin treatment that showed no differences in exocrine
pancreas proliferation rate [9,17], and supported by the
ADA/EASD/IDF consensually stating no need for modi-
fication of the current treatment recommendations on
the basis of the current study data [55].
Conclusions
The GIPRdn transgenic pig model recapitulated principal
clinical effects of liraglutide observed in type 2 diabetic
patients. However, the reduction of body weight gain
seen in adolescent pigs was more pronounced than the
body weight-reducing effect after treatment of adult
patients. Total alpha- and beta-cell mass was reduced
in liraglutide- vs. placebo-treated animals, but not whenrelated to body weight. Liraglutide treatment neither
stimulated beta-cell proliferation in the endocrine pan-
creas nor acinus-cell proliferation in the exocrine pan-
creas after a 90-day treatment trial in our adolescent
pre-diabetic pig model.
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